The field of bone disease, particularly age-related bone diseases such as osteoarthritis and osteoporosis, is a large and growing one as the global population increases and ages. The available treatment options tend to target the alleviation of symptoms rather than modifying the disease process itself. In other words, there's a high unmet medical need to identify a novel class of drug that could slow down the progression or even reverse the process of bone and cartilage degeneration. Arcarios BV aims to meet this need by using its proprietary technology platforms to discover and develop innovative drugs that will restore cartilage and bone.
Phone: +32 6 2054 3382
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Bristol’s CEO Christopher Boerner says business development is the company’s biggest spending priority as analysts raise concerns about growth, citing a need for BMS to do more deals.
Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.
CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.
